Acute myeloid leukemia therapeutics: CARs in the driver’s seat

por Mardiros, Armen, Brown, Christine E, Budde, L Elizabeth, Wang, Xiuli, Forman, Stephen J
Publicado 2013

Interferon-γ blockade in CAR T-cell therapy–associated macrophage activation syndrome/hemophagocytic lymphohistiocytosis

por Rainone, Michael, Ngo, Dat, Baird, John H., Budde, L. Elizabeth, Htut, Myo, Aldoss, Ibrahim, Pullarkat, Vinod
Publicado 2022

P1129: ACALABRUTINIB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) MARGINAL ZONE LYMPHOMA (MZL): RESULTS OF A PHASE 2, MULTICENTER, OPEN-LABEL TRIAL

por Strati, P., Coleman, M., Stevens, D., Ma, S., Patti, C., Levy, M., Lossos, I. S., Ramakrishnan Geethakumari, P., Lam, S., Calvo, R., Higgins, K., Budde, L.
Publicado 2022

P1454: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR THE TREATMENT OF RELAPSED OR REFRACTORY (R/R) MANTLE CELL LYMPHOMA (MCL) IN THE UNITED STATES (US)

por Locke, F., Hu, Z.-H., Gerson, J., Frank, M. J., Budde, L. E., Wang, M., Logan, B., Kloos, I., Siddiqi, R., Shah, J., Xu, H., Pasquini, M.
Publicado 2022

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphoma

por Siddiqi, Tanya, Wang, Xiuli, Blanchard, M. Suzette, Wagner, Jamie R., Popplewell, Leslie L., Budde, L. Elizabeth, Stiller, Tracey L., Clark, Mary C., Lim, Laura, Vyas, Vibhuti, Brown, Christine E., Forman, Stephen J.
Publicado 2021

P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

por Cheah, C. Y., Bartlett, N. L., Assouline, S., Schuster, S. J., Seog Kim, W., Shadman, M., Isufi, I., Yin, S., Doral, M. Y., Sit, J., Chen, V., Huang, H., Zhou, M., Wei, M. C., Budde, L. E.
Publicado 2022

S220: REAL-WORLD OUTCOMES OF BREXUCABTAGENE AUTOLEUCEL (BREXU-CEL) FOR RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA: A CIBMTR SUBGROUP ANALYSIS BY PRIOR TREATMENT

por Ahmed, Nausheen, Kambhampati, Swetha, Hamadani, Mehdi, Grover, Natalie, Shadman, Mazyar, Locke, Frederick, Gerson, James, Frank, Matthew J., Budde, L. Elizabeth, Wang, Michael, Hu, Zhen-Huan, Nunes, Ana, Dalton, David, Kloos, Ioana, Lee, Daniel, Xu, Hairong, Pasquini, Marcelo, Herrera, Alex F.
Publicado 2023

P1126: MOSUNETUZUMAB IS EFFICACIOUS AND WELL TOLERATED IN PATIENTS AGED <65 AND ≥65 YEARS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA AND ≥2 PRIOR THERAPIES: SUBGROUP ANALYSIS OF...

por Matasar, M., Bartlett, N. L., Sehn, L. H., Schuster, S. J., Assouline, S., Giri, P., Kuruvilla, J., Canales, M., Dietrich, S., Fay, K., Ku, M., Nastoupil, L. J., Wei, M. C., Yin, S., To, I., Turner, D., Huang, H., Min, J., Penuel, E., Budde, L. E.
Publicado 2022

P1078: MOSUNETUZUMAB DEMONSTRATES DURABLE RESPONSES IN PATIENTS WITH RELAPSED AND/OR REFRACTORY FOLLICULAR LYMPHOMA WHO HAVE RECEIVED ≥2 PRIOR THERAPIES: UPDATED ANALYSIS OF A PIVO...

por Sehn, Laurie H., Bartlett, Nancy L., Matasar, Matthew, Schuster, Stephen J., Assouline, Sarit, Kuruvilla, John, Shadman, Mazyar, Cheah, Chan, Fay, Keith, Ku, Matthew, Nastoupil, Loretta J., Wei, Michael, Yin, Shen, To, Iris, Hu, Nan, Min, Juliana, Penuel, Elicia, Belousov, Anton, Coimbra, Alexandre, Jemaa, Skander, Bender, Brendan, Turner, David, Elizabeth Budde, L.
Publicado 2023